Concepedia

SL Moulder

SM

Statistics

Publications

7

Citations

1.2K

H-Index

7

Active since

2007

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

University of California, San Francisco

University of California San Diego

SL Moulder is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and pharmacology.

Publications per year

2007–2021

7

Publications

7

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

Daniel J. McGrail, P.G. Pilié, N.U. Rashid et al. · Annals of Oncology · 2021 · 1.1K citations · Full text

, , +17

Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC)

RS Finn, Yuqiu Jiang, Hope S. Rugo et al. · Annals of Oncology · 2016 · 56 citations · Full text

, , +17

Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer

Gerald S. Falchook, SL Moulder, Jennifer J. Wheler et al. · Annals of Oncology · 2013 · 31 citations · Full text

, , +15

Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules

Alison Stopeck, SL Moulder, Suzanne F. Jones et al. · Journal of Clinical Oncology · 2007 · 21 citations

, , +15

Abstract P3-14-02: Phase 1 Dose-Escalation Study of the Heat Shock Protein 90 Inhibitor BIIB021 with Trastuzumab in HER2+ Metastatic Breast Cancer

Sagar Modi, RR Ismail-Khan, Pamela N. Münster et al. · Cancer Research · 2010 · 14 citations

, , +17

1–5 of 7